Ramoplanin Complex
(Synonyms: 雷莫拉宁) 目录号 : GC48025An antibiotic complex
Cas No.:76168-82-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ramoplanin complex is a mixture of ramoplanin A1, -A2, and -A3 originally isolated from Actinoplanes that has antibacterial activity.1,2,3 Ramoplanin complex is active against clinical isolates of the Gram-positive bacteria S. aureus, S. pyogenes, S. pneumoniae, and S. faecalis (MICs = 0.016-2 µg/ml) but not Gram-negative bacteria or C. albicans (MICs = ≥128 µg/ml).2 It inhibits cell wall synthesis in B. subtilis when used at a concentration of 0.5 µg/ml.1 Ramoplanin complex is effective against systemic S. pyogenes, S. pneumoniae, and S. aureus infections in mice with ED50 values of 0.081, 0.14, and approximately 25 mg/kg per day, respectively.
1.Cavalleri, B., Pagani, H., Volpe, G., et al.A-16686, a new antibiotic from actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristicsJ. Antibiot. (Tokyo)37(4)309-317(1984) 2.Pallanza, R., Berti, M., Scotti, R., et al.A-16686, a new antibiotic from actinoplanes. II. Biological propertiesJ. Antibiot. (Tokyo)37(4)318-324(1984) 3.Shin, D., Rew, Y., and Boger, D.L.Total synthesis and structure of the ramoplanin A1 and A3 aglycons: Two minor components of the ramoplanin complexProc. Natl. Acad. Sci. USA101(33)11977-11979(2004)
| Cas No. | 76168-82-6 | SDF | |
| 别名 | 雷莫拉宁 | ||
| Canonical SMILES | OC(C=C1)=CC=C1[C@H](C(N[C@H](CCCN)C(N[C@@]([C@H](O)C)([H])C(N[C@@H](C2=CC=C(O)C=C2)C(N[C@H](C3=CC=C(O)C=C3)C(NC([C@H](C)O)C(N[C@@H](CC4=CC=CC=C4)C(N[C@H](CCCN)C(N[C@@H](C5=CC=C(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O[C@]7([H])[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)C=C5)C8=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@@H](NC([C@@H](NC(/C=C\C=C\CCC)=O)CC(N)=O)=O)[C@@H](C(N)=O)OC([C@]([H])(C9=CC=C(O)C(Cl)=C9)NC([C@@H](C)NC([C@H](CC(C)C)NC(CNC([C@H](C%10=CC=C(O)C=C%10)NC([C@]([C@H](O)C)([H])N8)=O)=O)=O)=O)=O)=O)=O.OC(C=C%11)=CC=C%11[C@H](C(N[C@H](CCCN)C(N[C@@]([C@H](O)C)([H])C(N[C@@H](C%12=CC=C(O)C=C%12)C(N[C@H](C%13=CC=C(O)C=C%13)C(NC([C@H](C)O)C(N[C@@H](CC%14=CC=CC=C%14)C(N[C@H](CCCN)C(N[C@@H](C%15=CC=C(O[C@H]%16O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%16O[C@]%17([H])[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%17)C=C%15)C%18=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@@H](NC([C@@H](NC(/C=C\C=C\CC(C)C)=O)CC(N)=O)=O)[C@@H](C(N)=O)OC([C@]([H])(C%19=CC=C(O)C(Cl)=C%19)NC([C@@H](C)NC([C@H](CC(C)C)NC(CNC([C@H](C%20=CC=C(O)C=C%20)NC([C@]([C@H](O)C)([H])N%18)=O)=O)=O)=O)=O)=O)=O.OC(C=C%21)=CC=C%21[C@H](C(N[C@H](CCCN)C(N[C@@]([C@H](O)C)([H])C(N[C@@H](C%22=CC=C(O)C=C%22)C(N[C@H](C%23=CC=C(O)C=C%23)C(NC([C@H](C)O)C(N[C@@H](CC%24=CC=CC=C%24)C(N[C@H](CCCN)C(N[C@@H](C%25=CC=C(O[C@H]%26O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]%26O[C@]%27([H])[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%27)C=C%25)C%28=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@@H](NC([C@@H](NC(/C=C\C=C\CCC(C)C)=O)CC(N)=O)=O)[C@@H](C(N)=O)OC([C@]([H])(C%29=CC=C(O)C(Cl)=C%29)NC([C@@H](C)NC([C@H](CC(C)C)NC(CNC([C@H](C%30=CC=C(O)C=C%30)NC([C@]([C@H](O)C)([H])N%28)=O)=O)=O)=O)=O)=O)=O | ||
| 分子式 | C119H154ClN21O40 (for A2) | 分子量 | 2554.1 |
| 溶解度 | DMF: 10mg/mL,DMSO: 10mg/mL,DMSO:PBS (pH 7.2) (1:3): 0.25mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3915 mL | 1.9576 mL | 3.9153 mL |
| 5 mM | 0.0783 mL | 0.3915 mL | 0.7831 mL |
| 10 mM | 0.0392 mL | 0.1958 mL | 0.3915 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Total synthesis and structure of the ramoplanin A1 and A3 aglycons: two minor components of the Ramoplanin Complex
Proc Natl Acad Sci U S A 2004 Aug 17;101(33):11977-9.PMID:15175429DOI:10.1073/pnas.0401419101.
Ramoplanin is a potent antibiotic, first disclosed in 1984, that acts by inhibiting bacterial cell-wall biosynthesis. The original Ramoplanin Complex was shown to consist of a mixture of three closely related compounds, ramoplanin A1-A3, of which ramoplanin A2 is the most abundant. The structure of ramoplanin A2 was unambiguously established first through a series of extensive spectroscopic studies, allowing complete stereochemical assignments and subsequently providing a minor reassignment of the side-chain double-bond stereochemistry and, most recently, through total synthesis of authentic material. Here we report the total syntheses of the aglycons of the minor components of the Ramoplanin Complex, A1 and A3, which unambiguously establish their structure and provide an expected structural revision for the lipid side-chain double-bond stereochemistry.